Crossject SA

Paris Stock Exchange ALCJ.PA

Crossject SA Goodwill for the year ending December 31, 2023: USD 0.00

Crossject SA Goodwill is USD 0.00 for the year ending December 31, 2023, a 0.00% change year over year. Goodwill is the value attributed to intangible assets, such as brand reputation or customer relationships, acquired in a business combination.

Crossject SA Goodwill for the year ending December 31, 2022 was USD 0.00, a 0.00% change year over year.
Crossject SA Goodwill for the year ending December 31, 2021 was USD 0.00, a 0.00% change year over year.
Crossject SA Goodwill for the year ending December 31, 2020 was USD 0.00, a 0.00% change year over year.
Crossject SA Goodwill for the year ending December 31, 2019 was USD 0.00, a 0.00% change year over year.

Key data

Date	Goodwill	Total Assets	Current Liabilities	Total Non-Current Liabilities

Paris Stock Exchange: ALCJ.PA

Crossject SA

CEO	Mr. Patrick Alexandre
IPO Date	Feb. 20, 2014
Location	France
Headquarters	6 Rue Pauline Kergomard
Employees	105
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Clinical Trials Drugstores & Retail Pharmacies

Description

Crossject Société Anonyme develops needle-free injection systems. The company develops ZENEO, a needle-free, prefilled, and single-use auto-injector. Its clinical stage drugs comprise Sumatriptan, which is used for of treatment migraines and cluster headaches; Adrenaline for treating anaphylactic shock; Hydrocortisone that is used for treatment of acute adrenal crisis; Midazolam for treating epileptic seizure; Naloxone used for treatment of overdose; Apomorphine, for treating temporary paralysis in parkinson's disease; Methotrexate used for treatment of rheumatoid arthritis; and Terbutaline, for treating severe asthma crisis. The company was founded in 1997 and is based in Dijon, France.

Key trends

Past 5 years